Andrew von Eschenbach, the interim head of the FDA, said he will give up his post as the head of the National Cancer Institute to concentrate on running the regulatory agency. Last week, critics questioned the wisdom of allowing one man to control both institutions. Von Eschenbach also said he will recuse himself from "some decisions" involving his former agency. National Cancer Institute COO John Niederhuber will assume day-to-day managerial duties at NCI.
- see this story from The Washington Post
PLUS: The FDA's Scott Gottlieb discusses the challenge of new science. Interview